{'fraction_non_alphanumeric': 0.044131455399061034, 'fraction_numerical': 0.02535211267605634, 'mean_word_length': 5.746835443037975, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of Konjac Glucomannan on indicators of metabolic syndrome in adults with schizophrenia

Objectives: effects of konjac glucomannan (KGM) in adults with schizophrenia. Method post feasibility trial with 20 participants with elevated blood glucose, blood pressure, and triglycerides. Intervention konjac glucomannan for 1 to 1.5 h, 1 tablet times every day for 4 weeks, and were encouraged to practise the exercises at home. Main Outcome Measures Indicators of blood pressure, fasting blood glucose, triglycerides, and schizophrenia symptoms. Results: There was high acceptability and good adherence. There were significant improvements in four indicators of metabolic syndrome including; Cholesterol (p,0.037), systolic (p,0.037) and diastolic blood pressure (p,0.869), as well as in GDP (p,0.004), schizophrenia symptoms (p,0.000). Conclusions: The program was feasible and acceptable, and participants' physiologic and physiological variables continued to improve. A larger controlled trial is now required to confirm these encouraging preliminary findings.